Bromocyclohexane

We are Bromocyclohexane CAS:108-85-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:Bromocyclohexane
CAS.NO:108-85-0
Synonyms:Cyclohexyl Bromide
3-bromocyclohexane
Molecular Formula:C6H11Br
Molecular Weight:163.05600
 
Physical and Chemical Properties:
Density:1.324;
Melting point:-57oC;
Boiling point:166-167oC;
Flash point:145oF;
Index of Refraction:1.495;
 
Specification:
Appearance:Light yellow liquid
Purity(GC):≥99.0%
Moisture:≤0.1%
 
Package:250 kg/drum, can also be Packageaged according to customer requirements
Synthesis:Prepared by reacting cyclohexanol with hydrobromic acid or sodium bromide
Application:As an intermediate in organic synthesis

Bromocyclohexane


Related News: The Breakthrough Designation for the iLet Bionic Pancreas System contemplates configurations with most insulin analogs approved for pumping as well as dasiglucagon, Zealand Pharma’s stable pumpable glucagon analog, which has a unique stability profile in a ready-to-use aqueous solution.312753-53-0 Optimize the reaction and improve the production process to reduce the production cost. At the same time, strengthen the determination and analysis of impurities to improve product quality.2268-17-9 The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.Citidina 5'-monofosfato sal disódica CAS:6757-06-8 The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.International Chemical Investors Group (ICIG) recently announced it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation.

Related Products
Product Name
Guanosine 5′-monophosphate disodium salt View Details
hexamethyldisilazane View Details
2-(2-amino-1,3-thiazol-4-yl)acetic acid View Details
12-bromododec-1-ene manufacturer 4-Bromobenzotrifluoride manufacturer 4-chloropyridine-2-carbonitrile manufacturer Phenetole manufacturer 2,4,5-trimethylthiazole manufacturer